<html>
<head>
	<meta name="Sperowider-ArchiveRoot" content="../../../../../">
<meta name="Sperowider-DocRoot" content="../../../">
<meta name="Sperowider-OriginalURL" content="http://www.erowid.org/archive/rhodium/chemistry/glennon.pubs.html">
<title>Richard A Glennon</title>
	<link rel="StyleSheet" href="../rhodium.css" type="text/css">
</head>

<body>
<div style="border:black solid 1px;">
<div style="border:white solid 1px; padding:.25em; color: white; font: 700 9pt arial,sans-serif; background-color: darkblue;">
This file is a part of the Rhodium site archive.  This Aug 2004 static snapshot is hosted by Erowid<br>
as of May 2005 and is not being updated.  <a href="../index.html" style="color:white;">&gt; &gt; Back to Rhodium Archive Index &gt; &gt; </a>
</div>
</div>

<center>
<table border="0" width="750">
<tr>
<td>

<hr>
<center>
	<h1>Richard A Glennon</h1>
<hr>
<a href="index.html">[ Back to the Chemistry Archive ]</a>
</center>

<h3>Publications</h3>

<P>  1. Coburn, R. A.; Carapellotti, R. A.; Glennon, R. A., A PPP <FONT FACE="Symbol">&#112;</FONT>-SCF Variable Integral Study of Mesoionic Analogs Based on Six Membered Ring Mesoionic Systems.  J.  Heterocyclic  Chem. 1973, <U>10</U>, 479.</P>
<P>  2.&#9;Coburn, R. A.; Glennon, R. A., Synthesis and Properties of Mesoionic Thiazolo[3,2-a]pyrimidin-5,7-diones; J. Heterocyclic Chem. 1973, <U>10</U>, 487.</P>
<P>  3.&#9;Coburn, R. A.; Glennon, R. A., Synthesis and in vitro Antibacterial Properties of Mesoionic Thiazolo[3,2-a] pyrimidin-5,7-diones and Mesoionic 1,3,4- Thiadiazolo[3,2a]pyrimidin-5,7-diones; J.Pharm.Sci. 1973, <U>62</U>, 1785.</P>
<P>  4.&#9;Coburn, R. A.; Bhooshan, B.; Glennon, R. A., The Preparation of 2-Alkylamino-1,3,4-thiadiazoles. J. Org. Chem. 1973, <U>38</U>, 3947.</P>
<P>  5.&#9;Coburn, R. A.; Glennon, R. A.; Chmielewicz, Z., <I>In vitro</I> Antibacterial Activity of Mesoionic 1,3,4-Thiadiazolo [3,2a]pyrimidin-5,7-diones; J. Med. Chem. 1974, <U>17</U>, 1025.</P>
<P>  6.&#9;Glennon, R. A., A Quantum Chemical Investigation of the <FONT FACE="Symbol">&#112;</FONT> Electronic Structure of the Hallucinogenic N,N-Dimethyltryptamines; Res. Commun. Chem. Path.  Pharmacol. 1974, <U>9</U>, 185.</P>
<P>  7.&#9;Glennon, R. A.; Von Strandtmann, M., Cyclodehydration of N-Heteroarylcarbamoylmethylbenzamides; J. Heterocyclic Chem. 1975, <U>12</U>, 135.</P>
<P>  8.&#9;Glennon, R. A.; Gessner, P. K., The Electronic and Serotonin Receptor Binding Affinity properties of N,N-Dimethyltryptamine Analogs; Res. Commun. Chem. Path.  Pharmacol. 1977, <U>18</U>, 453.</P>
<P>  9.&#9;Kier, L. B.; Glennon, R. A., Psychotomimetic Phenalkylamines as Serotonin Agonists: An SAR Analysis; Life Sciences 1978,  <U>20</U>, 1589.</P>
<P> 10.&#9;Glennon, R. A.; Martin, B.; Johnson, K.; End, D., 7,N,N-Trimethyltryptamine: A Selective Inhibitor of Synaptosomal Serotonin Uptake; Res. Commun. Chem., Path.  Pharmacol. 1978, <U>19</U>, 161.</P>
<P> 11.&#9;Glennon, R. A.; Liebowitz, S. M.; Mack, E. C., Serotonin Receptor Binding Affinities of Several &#9;Hallucinogenic Phenalkylamine and N,N-Dimethyltryptamine Analogs. J.  Med. Chem. 1978, <U>21</U>, 822.</P>
<P> 12.&#9;Glennon, R. A.; Kier, L. B., LSD Analogs as Serotonin Antagonists: A Molecular Connectivity SAR Analysis; Eur. J. Med. Chem. 1978, <U>13</U>, 219.</P>
<P> 13.&#9;Glennon, R. A.; Rogers, M. E.; Bass, R. G.; Ryan, S. B., Mesoionic Xanthine Analogs as Inhibitors of Cyclic AMP Phosphodiesterase; J. Pharm. Sci. 1978, <U>67</U>, 1762.</P>
<P> 14.&#9;Watson,H.; Glennon, R.A., Common Drug Interactions; Anesthesia Update Series 1978, <U>6</U>, 1.</P>
<P> 15.&#9;Glennon, R. A.; Kier, L. B.; Shulgin, A. T., A Molecular Connectivity Analysis of Mescaline Analogs; J. Pharm. Sci. 1979, <U>68</U>, 906.</P>
<P> 16.&#9;Glennon, R. A.; Rosecrans, J. A.; Young, R.; Gaines, J., Hallucinogens as Discriminative Stimuli: Generalization of a 5-Methoxy DMT stimulus with DOM. Life Sciences 1979, <U>24</U>, 993.</P>
<P> 17.&#9;Glennon, R. A.; Bass, R. G.; Schubert, E., Alkylation of Thiazolo[3,2-a]pyrimidin-5,7-diones; J. Heterocyclic Chem. 1979, <U>16</U>, 903.</P>
<P> 18.&#9;Glennon, R. A., The Effect of Chirality on Serotonin Receptor Affinity; Life Sciences, 1979, <U>24</U>, &#9;1487.</P>
<P> 19.&#9;Glennon, R. A., A Similarity Between Rat Fundus Serotonin Receptors and Brain Serotonin Binding Sites; Res. Commun. Psychol. Psychiat. Behav., 1979, <U>4</U>, 333.</P>
<P> 20.&#9;Glennon, R. A.; Gessner, P. K., Serotonin Receptor Affinities of Tryptamine Analogs; J. Med. Chem. 1979, <U>22</U>, 428.</P>
<P> 21.&#9;Glennon, R. A.; Gessner, P. K.; Godse, D.; Kline, B., Bufotenine Esters, J. Med.  Chem. 1979, <U>22</U>, 1414.</P>
<P> 22.&#9;Rosecrans, J. A.; Glennon, R. A., Drug Induced Cues in Studing Mechanisms of Drug Action. Neuropharmacology 1979, <U>18</U>, 981.</P>
<P> 23.&#9;Glennon, R. A.; Rogers, M. E.; El-Said, M. K., Imidazo[1,2a]-pyrimidines and 1,2,4-Triazolo[1,5-a] pyrimidines: Two new examples of mesoionic xanthine analogs.  J. Heterocyclic Chem. &#9;1980,  <U>17</U>, 337.</P>
<P> 24.&#9;Glennon, R. A.; Liebowitz, S. M.; Anderson III, G. M., Serotonin Receptor Affinities of Psychoactive Phenalkylamine Analogs; J. Med. Chem. 1980, <U>23</U>, 294.</P>
<P> 25.&#9;Minnema, D.; Krynock, G.; Young, R.; Glennon, R. A.; Rosecrans, J. A., Role of Dorsal Raphe Neurons to the Ability of LSD to act as a Discriminative Stimulus.  J. Alcohol Drug Abuse 1980, <U>1</U>, 29.</P>
<P> 26.&#9;Glennon, R. A.; Young, R.; Rosecrans, J. A.; Kallman, M. J., Hallucinogenic Agents as Discriminative Stimuli: A Correlation with Serotonin Receptor Affinities.  Psychopharmacology 1980, <U>68</U>, 155.</P>
<P> 27.&#9;Glennon, R. A.; Liebowitz, S. M.; Doot, D. L.; Rosecrans, J. A., Demethyl Analogues of Psychoactive Methoxy phenylisopropylamines: Synthesis and Serotonin Receptor Affinities; J. Med. Chem. 1980, <U>23</U>, 990.</P>
<P> 28.&#9;Glennon, R. A.; Schubert, E.; Jacyno, J. M., Studies on Several 7-Substituted N,N-Dimethyltryptamines; J. Med. Chem. 1980, <U>23</U>, 1222.</P>
<P> 29.&#9;Glennon, R. A.; Doot, D. L.; Young, R., DOM and Related  2,5-Dimethoxy-4-alkylphenylisopropylamines: Behavioral and Serotonin Receptor  Properties; Pharmacol. Biochem. Behav. 1981, <U>14</U>, 287.</P>
<P> 30.&#9;Glennon, R. A.; Rogers, M. E.; Smith, J. D.; El-Said, M. K.; Egle, J. L., Mesoionic Xanthine Analogues: Phosphodiesterase Inhibitory and Hypotensive Activity, J. Med. Chem. 1981, <U>24</U>, 658.</P>
<P> 31.&#9;Glennon, R. A.; Salley, J. J.; Steinsland, O. S.; Nelson, S., Synthesis and Evaluation of Novel Alkylpiperazines as Potential Dopamine Antagonists; J. Med. Chem. 1981, <U>24</U>, 678.</P>
<P> 32.&#9;Glennon, R. A.; Gaines, J. J.; Rogers, M. E., Benz-fused Mesoionic Xanthine Analogues as Inhibitors of Cyclic-AMP Phosphodiesterase.  J. Med. Chem. 1981, <U>24</U>, 766.</P>
<P> 33.&#9;Rogers, M. E.; Glennon, R. A.; Smith, J. D.; Boots, M. R.; Nanavati, N.; Maconaughey, J. E.; Aub, D.; Thomas, S.; Bass, R.  G.; Mbagwu, G., Mesoionic Purinone Analogues as Inhibitors of Cyclic-AMP Phosphodiesterase:  A Comparison of Several Ring Systems; J. Med. Chem.  1981, <U>24</U>, 1284.</P>
<P> 34.&#9;Glennon, R. A.; Showalter, D., The Effects of Cathinone and Several Related Derivatives on Locomotor Activity; Res. Commun.  Subst. Abuse 1981, <U>2</U>, 186.</P>
<P> 35.&#9;Glennon, R. A.; Rosecrans, J. A., Speculations on the Mechanism of Action of Hallucinogenic Indolealkylamines; Neursci. Biobehav. Rev. 1981, <U>5</U>, 197.</P>
<P> 36.&#9;Young, R.; Glennon, R. A.; Rosecrans, J. A., Discriminative Stimulus Properties of the Hallucinogenic Agent DOM; Commun. Psychopharmacol. 1981, <U>4</U>, 501.</P>
<P> 37.&#9;Glennon, R. A., Serotonin Receptor Interactions of Harmaline and Several  Related-Carbolines; Life Sciences 1981, <U>29</U>, 861.</P>
<P> 38.&#9;Glennon, R. A.; Schubert, E.; Bass, R. G., Synthesis of Mesoionic Xanthine Nucleosides, Tetrahedron Lett. 1981, <U>29</U>, 2753.</P>
<P> 39.&#9;Domelsmith, L. N.; Eaton, T. A.; Houk, K. N.; Anderson, G. M.; Glennon, R. A.; Shulgin, A.T.; Castagnoli, N.; Kollman, P. A., Relationship Between Physical Properties and Pharmacological Actions of Amphetamine Analogues. J. Med. Chem.  1981, <U>24</U>, 1414.</P>
<P></P>
<P> 40.&#9;Glennon, R. A.; Rosecrans, J. A.; Young, R., Behavioral Properties of Psychoactive Phenylisopropylamines. Eur. J. Pharmacol. 1981, <U>76</U>, 353.</P>
<P> 41.&#9;Glennon, R. A.; Young, R.; Benington, F.; Morin, R. D., Hallucinogens as Discriminative Stimuli:  A Comparison of 4-OMe DMT and 5-OMe DMT with their Methylthio Counterparts. Life Sciences 1982, <U>30</U>, 465.</P>
<P> 42.&#9;Glennon, R. A.; Jacyno, J. M.; Salley, J. J., 2,3-Dihydro and Carbocyclic Analogues of Tryptamines: Interaction with Serotonin Receptors. J. Med. Chem. 1982, <U>25</U>, 68.</P>
<P> 43.&#9;Glennon, R. A.; Rosecrans, J. A.; Young, R., Discriminative Stimulus Properties of  DOM and Several Molecular Modifications. Pharmacol. Biochem. Behav. 1982, <U>16</U>, 553.</P>
<P> 44.&#9;Glennon, R. A.; Young, R.; Rosecrans, J. A., A Comparison of the Behavioral Effects of DOM Homologs. Pharmacol. Biochem. Behav. 1982, <U>16</U>, 557.</P>
<P> 45.&#9;Glennon, R. A.; Liebowitz, S. M., Serotonin Receptor Affinity of Cathinone Analogues. J. Med. Chem. 1982, <U>25</U>, 393.</P>
<P> 46.&#9;Young, R.; Rosecrans, J. A.; Glennon, R. A., Comparative Discriminative Stimulus Effects of 5-Methoxy-N,N-dimethyltryptamine and LSD.  Life Sciences 1982, <U>30</U>, 2057.</P>
<P> 47.&#9;Glennon, R. A.; Young, R.; Rosecrans, J. A.; Anderson, G. M., Discriminative Stimulus Properties of  MDA Analogs.  Biol. Psychiat. 1982, <U>17</U>, 807.</P>
<P> 48.&#9;Salley, J. J.; Glennon, R. A., Studies on Simplified Ergoline Derivatives. A General Six-step Synthesis of Phenyl- Substituted 4-Methyl-3,4a,5,6,10b-hexahydrobenzo[f]quinolin-1(2H)-one Analogs. J. Heterocyclic Chem.  1982, <U>19</U>, 545.</P>
<P> 49.&#9;Glennon, R. A.; Young, R., A Comparison of the Behavioral Properties of Di- and Tri-methoxyphenylisopropyl amines. Pharmacol. Biochem. Behav. 1982, <U>17</U>, 603.</P>
<P> 50.&#9;Glennon, R. A.; Young, R.; Benington, F.; Morin, R. D., The Behavioral and Serotonin Receptor Properties of 4-Substituted Derivatives of the Hallucinogen 1-(2,5-Dimethoxyphen-yl)-2-aminopropane. J. Med. Chem. 1982, <U>25</U>, 1163.</P>
<P> 51.&#9;Glennon, R. A.; Rosecrans, J. A., Indolealkylamine and Phenalkylamine Hallucinogens: A Brief Overview. Neurosci. Biobehav.  Rev. 1982, <U>6</U>, 489.</P>
<P> 52.&#9;Lund, M. Q.; Kier, L. B.; Glennon, R. A.; Egle, J. L., Preliminary Studies of mesoionic 3-(substituted aryl) pseudo oxatriazoles as potential antihypertensive agents.  J.  Med. Chem.  1982, <U>25</U>, 1503.</P>
<P> 53.&#9;Kline, T.B.; Benington, F.; Morin, R.D.; Beaton, J.M.; Glennon, R.A.; Domelsmith, L.;  Houk, K.N.; Rozeboom, M.D., Structure-activity relationships for hallucinogenic N,N-&#9;dialkyltryptamines: Photoelectron spectra and 5-HT receptor affinities of methylthio and methylenedioxy derivatives.  J. Med. Chem. 1982, <U>25</U>, 1381.</P>
<P> 54.&#9;Glennon, R. A.; Young, R.; Jacyno, J. M., Indolealkylamine and Phenalkylamine  Hallucinogens: Effect of  <FONT FACE="Symbol">&#97;</FONT>-Methyl and N-Methyl Substituents on Behavioral Activity.  Biochem. Pharmacol. 1983, <U>32</U>, 1267.</P>
<P> 55.&#9;Glennon, R. A.; Young, R.; Jacyno, J. M.; Slusher, R. M.; Rosecrans, J. A., DOM-Stimulus Generalization to LSD and other Hallucinogenic Indolealkylamines.  Eur. J. Pharmacol. 1983, <U>86</U>, 453.</P>
<P> 56.&#9;Glennon, R. A.; Jacyno, J. M.; Young, R., A Comparison of the Behavioral Properties of  (<FONT FACE="Symbol">&#177;</FONT>)-, (+)- and (-)-5-Methoxy-<FONT FACE="Symbol">&#97;</FONT>-methyltryptamine.  Biol. Psychiat. 1983, <U>18</U>, 493.</P>
<P> 57.&#9;Young, R.; Rosecrans, J. A.; Glennon, R. A., Behavioral Effects of 5-Methoxy-N,N-dimethyltryptamine and Dose-Dependent Antagonism by BC-105.   Psychopharmacology 1983, <U>80</U>, 156.</P>
<P> 58.&#9;Schubert, E. M.; Bass, R. G.; Glennon, R. A., Synthesis of Mesoionic Xanthine Nucleosides. Nucleosides/ Nucleotides 1983, <U>2</U>, 127.</P>
<P> 59.&#9;Glennon, R. A.; Rosecrans, J. A.; Young, R., Drug-induced Discrimination: A description of  the Paradigm and a Review of its Specific Application to the Study of Hallucinogenic Agents.  Med. Res. Rev. 1983, <U>3</U>, 289.</P>
<P> 60.&#9;Glennon, R. A.; Young, R.; Rosecrans, J. A., Antagonism of the Effects of the Hallucinogen DOM and the Purported Serotonin Agonist Quipazine by 5-HT2 Antagonists.  Europ. J. Pharmacol. 1983, <U>91</U>, 189.</P>
<P> 61.&#9;Glennon, R. A.; Young, R.; Jacyno, J. M.; Nelson, D. Synthesis and Evaluation of a Novel Series of N,N-Di- methylisotryptamines. J.  Med. Chem. 1984, <U>27</U>, 41.</P>
<P> 62.&#9;Mbagwu, G.; Bass, R. G.; Glennon, R. A., Carbon-13 Nuclear Magnetic Resonance Spectra of some Mesoionic Xanthine Analogs.  Org. Mag. Res. 1983, <U>21</U>, 527.</P>
<P> 63.&#9;Glennon, R. A.; Young, R., MDA:  A Psychoactive Agent with Dual Stimulus Effects. Life Sci. 1984, <U>34</U>, 379.</P>
<P> 64.&#9;Glennon, R. A.; Young, R., Further Investigation of the Discriminative Stimulus Properties of MDA.  Pharmacol. Biochem. Behav. 1984, <U>20</U>, 501.</P>
<P> 65.&#9;Wood, P. L.; Pilapil, C.; LaFaille, F.; Nair, N. P.; Glennon, R. A., Unique [<SUP>3</SUP>H]Tryptamine Binding Sites in Rat Brain: Distribution and Pharmacology.  Arch. Int. Pharmacodyn.  1984, <U>268</U>, 194.</P>
<P> 66.&#9;Glennon, R. A.; Young, R.; Soine, W., 1-(2,3-Methylenedioxyphenyl)-2-aminopropane: A Preliminary Investigation. Gen. Pharmacol. 1984, <U>15</U>, 361.</P>
<P> 67.&#9;Aceto, M.; Rosecrans, J. A.; Young, R.; Glennon, R. A., Similarity Between  (+)-Amphetamine and  Amfonelic Acid. Pharmacol. Biochem. Behav. 1984, <U>20</U>, 635.</P>
<P> 68.&#9;Young, R.; Dewey, W. L.; Glennon, R. A., Stereoselective Stimulus Effects of 3-Methylflunitrazepam and Pentobarbital. Life Sci. 1984.</P>
<P> 69.&#9;Schechter, M. D.; Rosecrans, J. A.: Glennon, R. A., Comparison of the Behavioral Effects of Cathinone, Amphetamine and Apomorphine.  Pharmacol. Biochem. Behav.  1984, <U>20</U>, 181.</P>
<P> 70.&#9;Glennon, R. A.; Schechter, M. D.; Rosecrans, J. A., Discriminative Stimulus Properties of  <I>S</I>(-)- and <I>R</I>(+)-Cathinone, (+)-Cathine, and Several Structural Modifications.  Pharmacol. Biochem. Behav. 1984, <U>21</U>, 1.</P>
<P> 71.&#9;Glennon, R. A.; Young, R., MDA:  An Agent that Produces Stimulus Effects Similar to those of 3,4-DMA, LSD and Cocaine. Europ. J. Pharmacol. l984, <U>99</U>, 249.</P>
<P> 72.&#9;Shannon, M.; Battaglia, G.; Glennon, R. A.; Titeler, M., 5-HT<SUB>1</SUB> and 5-HT<SUB>2 </SUB> Receptor Binding Properties of Derivatives of the Hallucinogen 1-(2,5-Dimethoxyphenyl)-2-aminopropane.   Eur. J. Pharmacol. 1984, <U>102</U>, 23.</P>
<P> 73.&#9;Glennon, R. A.; Hauck, A.; McKenney, J. D.; Young, R., Structure-Activity Relationships of Amphetamine Analogs Using Drug Discrimination Methodology.  Pharmacol. Biochem. Behav. 1984, <U>21</U>, 895.</P>
<P> 74.&#9;Glennon, R. A.; Tejani, S. Mesoionic Nucleosides:Studies on Mesoionic Imidazo[2,1-b]1,3-thiazine Derivatives. Nucleosides/Nucleotides 1984, <U>3</U>, 389.</P>
<P> 75.&#9;Glennon, R. A.; Tejani, S.; Padgett, W.; Daly, J. W., Mesoionic Xanthine Analogues as Antagonists of Adenosine Receptors.  J. Med. Chem. 1984, <U>27</U>, 1364.</P>
<P> 76.&#9;Glennon, R. A.; Titeler, M.; McKenney, J. D., Evidence for 5-HT<SUB>2</SUB> Involvement in the Mechanism of Action of Hallucinogenic Agents.  Life Sci. 1984, <U>35</U>, 2505.</P>
<P> 77.&#9;Glennon, R. A.; McKenney, J. D.; Young, R., Discriminative Stimulus Properties of the &#9;Serotonin Agonist 1-(3-Trifluoromethylphenyl)piperazine (TFMPP).  Life Sci.  1984, <U>35</U>, 1475.</P>
<P> 78.&#9;Glennon, R. A.; Young, R.; Hauck, A. E., Structure-Activity Studies on Methoxy-Substituted Phenylisopropylamines Using Drug Discrimination Methodology.  Pharmacol. Biochem. Behav. 1985, <U>22</U>, 723.</P>
<P> 79.&#9;Titeler, M.; Herrick, C.; Lyon, R. A.; McKenney, J. D.; Glennon, R. A. [<SUP>3</SUP>H]DOB: A specific radioligand for 5-HT<SUB>2</SUB> receptors. Eur. J. Pharmacol. 1985, <U>117</U>, 145.</P>
<P> 80.&#9;Young, R.; Glennon, R. A.; Brase, D.; Dewey, W.  L.  Potencies of diazepam metabolites in generalizing to the diazepam discriminative stimulus.  Life Sci.  1985, <U>39</U>, 17.</P>
<P> 81.&#9;Glennon, R. A.; Hauck, A. E.  Mechanistic studies on DOM as a discriminative stimulus. Pharmacol. Biochem. Behav. 1985, <U>23</U>, 937.</P>
<P> 82.&#9;Schubert, E. M.; Schram, K. H.; Glennon, R. A.  Mass spectrometry of modified nucleic acid bases and nucleosides. Class II mesoionic nucleosides and bases derived from thiazolo[3,2-a]pyrimidine-5,7-diones.  J. Heterocyclic. Chem. 1985, <U>22</U>, 889.</P>
<P> 83.&#9;Schechter, M. D.; Glennon, R. A.  Cathinone, cocaine and methamphetamine: Similarity of behavioral effects.  Pharmacol.  Biochem. Behav.. 1985, <U>22</U>, 913.</P>
<P> 84.&#9;Mbagwu, G. O.; Bass, R. G.; Glennon, R. A. Studies of amine-induced ring-opening of some mesoionic xanthines, J. Heterocyclic Chem. 1985, <U>22</U>, 465.</P>
<P> 85.&#9;Glennon, R. A.; McKenney, J. D.; Lyon, R. A.; Titeler, M 5-HT<SUB>1</SUB> and 5-HT<SUB>2</SUB> binding  characteristic of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogs  J. Med.  Chem.  &#9;1986, <U>29</U>, 194.</P>
<P> 86.&#9;McKenney, J. D.; Glennon, R. A.  TFMPP may produce its stimulus effects via a 5-HT<SUB>1B</SUB> mechanism.  Pharmacol. Biochem. Behav.  1986, <U>24</U>, 43.</P>
<P> 87.&#9;Lyon, R. A.; Titeler, M.; Mckenney, J. D.; Magee, P. S.; Glennon, R. A.  Synthesis and evaluation of phenyl- and benzolypiperazines as potential serotonergic agents.  J.  Med.  Chem. 1986, <U>29</U>, 630.</P>
<P> 88.&#9;Young, R.; Glennon, R. A.; Amphetamine and related phenalkylamines as discriminative stimuli: A review of the literature. Med. Res. Rev. 1986, <U>6</U>, 99.</P>
<P> 89.&#9;Lyon, R. A.; Glennon, R. A.; Titeler, M.  3,4-Methylenedioxymethamphetamine (MDMA): Stereoselective interactions at brain 5-HT<SUB>1</SUB> and 5-HT<SUB>2</SUB> sites.  Psychopharmacology 1986, <U>88</U>, &#9;525.</P>
<P> 90.&#9;Glennon, R. Discriminative stimulus properties of the 5-HT<SUB>1A</SUB> agonist 8-OH DPAT. Life  Sci. 1986, <U>39</U>, 825.</P>
<P> 91.&#9;Glennon, R. A.  Discriminative stimulus properties of the serotonergic agent 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI).  Pharmacol. Biochem.  Behav.  1986, <U>25</U>, 135.</P>
<P> 92.&#9;Kalix, P.; Glennon, R. A.  Further evidence for an amphetamine-like mechanism of action of the &#9;alkaloid cathinone. Biochem. Pharmacol.  1986, <U>35</U>, 3015.</P>
<P> 93.&#9;Glennon, R. A.  Discriminative stimulus properties of phenylisopropylamine derivatives. Drug and Alcohol Depend.  1986, <U>17</U>, 119.</P>
<P>  94.&#9;Glennon, R. A.; Titeler, M.; Young, R. A.  Structure-activity relationships and mechanism of action of hallucinogenic agents based on drug discrimination and radioligand binding studies. Psychopharmacol. Bull. 1986, 953-959.</P>
<P>  95.&#9;Glennon, R. A.; Slusher, R. M.; Lyon, R. A.; Titeler, M.; McKenney, J. D.  5-HT<SUB>1</SUB> and 5-HT2 binding characteristics of some quipazine analogues.  J. Med. Chem. 1986, <U>29</U>, 2375-2380.</P>
<P>  96.&#9;Young, R.; Rosecrans, J. A.; Glennon, R. A.;  Further studies on the dose-dependent  stimulus sroperties of 5-methoxy-N,N-dimethyltryptamine.  Pharmacol. Biochem. Behav. 1986, <U>25</U>, 1207-1210.</P>
<P>  97.&#9;Rasmussen, K.; Glennon, R. A.; Aghajanian, G. K.;  Phenethylalamine hallucinogens in the locus coeruleus: potency of action correlates with rank order of 5-HT<SUB>2</SUB> binding affinity Eur. J. Pharmacol. 1986, <U>132</U>, 79-82.</P>
<P>  98.&#9;Glennon, R. A.  Central serotonin receptors as targets for drug research.  J. Med.  Chem. 1987, <U>30</U>, 1-12.</P>
<P>  99.&#9;Glennon, R. A.; Little, P. J.; Rosecrans, J. R.; Yousif, M. Y. The effect of MDMA ("Ecstasy") and its optical isomers on schedule-controlled responding in mice.  Pharmacol. Biochem. Behav. 1987, <U>26</U>, 425.</P>
<P>100.&#9;Glennon, R. A.; Titeler, M.; Seggel, M. R.; Lyon, R. A. N-Methyl derivatives of the 5-HT<SUB>2</SUB> antagonist 1-(4-bromo-2,5-dimethoxyphenyl)-2-aminopropane. J. Med.  Chem. 1987,  <U>30</U>, 930-932.</P>
<P>101.&#9;Glennon, R. A.; Yousif, M. Y.; Naiman, N.; Kalix, P. Methcathinone: A new and potent amphetamine-like agent. Pharmacol. Biochem. Behav. 1987, <U>26</U>, 547-551.</P>
<P>102.&#9;Kerdawy, M.; Bayomi, S.; Shehata, I; Glennon, R. A. Condensed 1,2,3-triazines: 1,3,4-&#9;Thiadiazolo[3,2-a]-1,3, 5-triazines and isoxazolo[2,3-a]-1,3,5-triazines. J.  Heterocyclic  Chem. 1987, <U>24</U>, 501-504.</P>
<P>103.&#9;Rosecrans, J. A.; Glennon, R. A. The effect of MDA and MDMA ("Ecstasy") isomers in combination with pirenperone on operant responding in mice.  Pharmacol. Biochem. Behav. 1987, <U>28</U>, 39-42.</P>
<P>104.&#9;Shehata, I.; Glennon, R. A. Mesoionic isoxazolo[2,3-a]pyrimidindiones and 1,3,4-oxadiazolo[3,2-a] pyrimidindiones as potential adenosine antagonists. J. Heterocyclic  Chem. 1987, <U>24</U>, 1291-1295.</P>
<P>105.&#9;Seggel, M. R.; Qureshi, G. D.; Glennon, R. A. Effect of 5-HT<SUB>2</SUB>-selective agonists on cat  platelet &#9;aggregation. Life Sci. 1987, 1077-1081.</P>
<P>106.&#9;Titeler, M.; Lyon, R. A.; Davis, K. H.; Glennon, R. A. Selectivity of serotonergic drugs for multiple brain 5-HT receptors: Role of [3H]DOB, a 5-HT<SUB>2</SUB> agonist radioligand. Biochem. Pharmacol. 1987, <U>36</U>, 3265-3271.</P>
<P>107.&#9;Young, R.; Glennon, R. A.; Dewey, W. L.; Effects of pyrazolopyridines and a triazolopyridazine on the pentobarbital discriminative stimulus. Psychopharmacology, 1987,  <U>93</U>, 494-497.</P>
<P>108.&#9;Young, R.; Glennon, R. A.; Stimulus properties of benzodiazepines: Correlations with binding affinities, therapeutic potencies, and structure-activity relationships.  Psychopharmacology, 1987, &#9;<U>93</U>, 529-533.</P>
<P>109.&#9;Glennon, R. A.; Seggel, M. R.; Soine, W. H.; Lyon, R. A. Davis, K.; Titeler, M.    [<SUP>125</SUP>I]-1-(2,5-Dimethoxy-4-iodophenyl)-2-aminopropane: An iodinated radioligand that  specifically labels the agonist high-affinity state of 5-HT<SUB>2</SUB> serotonin receptors. J. Med. Chem.   1988, <U>31</U>, 5-7.</P>
<P>110.&#9;Titeler, M.; Lyon, R. A.; Glennon, R. A. Radioligand binding evidence implicates the brain 5-HT<SUB>2</SUB> receptor as a site of action for LSD and phenylisopropylamine hallucinogens.  Psychopharmacology, 1988, <U>94</U>, 213-216.</P>
<P>111.&#9;Lyon, R. A.; Titeler, M.; Seggel, M. R.; Glennon, R. A. Indolealkylamine analogs share 5-HT<SUB>2</SUB> binding characteristics with phenalkylamine hallucinogens. Eur. J. Pharmacol. 1988,  <U>145</U>, 291-296.</P>
<P>112.&#9;Glennon, R. A.; Pierson, M. E.; McKenney, J. D. Stimulus generalization of  1-(3-trifluoromethylphenyl) piperazine (TFMPP) to propranolol, pindolol, and mesulergine.  Pharm. Biochem. Behav. 1988, <U>29</U>, 197-199.</P>
<P>113.&#9;Glennon, R. A.; Yousif, M.; Patrick, G. Stimulus properties of 1-(3,4-methylenedioxyphenyl)-2-aminopropane (MDA) analogs. Pharmacol. Biochem.   Behav. 1988, <U>29</U>, 443-449.</P>
<P>114.&#9;Glennon, R.A.; Titeler, M.; Lyon, R.A.; Slusher, R.M. N,N-Di-<I>n</I>-propylserotonin: Binding at serotonin sites and a comparison with 8-hydroxy-2-(di-<I>n</I>-propylamino)tetralin. J. Med. Chem. 1988, <U>31</U>, 867-869.</P>
<P>115.&#9;Kalix, P.; Yousif, M. Y.; Glennon, R. A. Differential effect of the enantiomers of methylenedioxyamphetamine (MDMA) on the release of radioactivity from  [<SUP>3</SUP>H]dopamine-prelabeled rat striatum. Res. Commun. Substance Abuse 1988, <U>9</U>, 45-51.</P>
<P>116.&#9;Glennon, R. A.; Titeler, M.; Lyon, R. A. A preliminary investigation of the psychoactive agent 4-bromo-2,5-dimethoxyphenethylamine: A potential drug of abuse. Pharmacol.  Biochem. Behav. 1988, <U>30</U>, 597-601.</P>
<P>117.&#9;Glennon,  R. A.; Naiman, N. A.; Lyon, R. A.; Titeler, M. Arylpiperazine derivatives as high-affinity serotonin 5-HT<SUB>1A</SUB> ligands. J. Med. Chem. 1988,<U> 31</U>, 1968-1971.</P>
<P>118.&#9;Glennon, R. A.; Naiman, N. A.; Pierson, M. E.; Titeler, M.; Lyon, R. A. NAN-190: An arylpiperazine analog that antagonizes the stimulus effects of the 5-HT<SUB>1A</SUB> agonist 8-hydroxy-2-(di-<I>n</I>-propylamino)tetralin. Eur. J. Pharmacol. 1988, <U>154</U>, 339-341.</P>
<P>119.&#9;Glennon, R. A.; Ismaiel, A. M.; Martin, B.; Poff, D.; Sutton, M. A preliminary behavioral investigation of PMMA, the 4-methoxy analog of methamphetamine. Pharmacol. Biochem. Behav. 1988, 31, 9-13.</P>
<P>120.&#9;Glennon, R. A.; Naiman, N. A.; Pierson, M. E.; Titeler, M.; Lyon, R. A.; Herndon, J. L.; Misenheimer, B. Stimulus properties of arylpiperazines: NAN-190, a potential 5-HT<SUB>1A</SUB> serotonin antagonist. Drug Dev. Res. 1989, <U>16</U>, 335-343.</P>
<P>121.&#9;Naiman, N. A.; Lyon, R. A.; Bullock, A. E.; Rydeleck, L. T.; Titeler, M.; Glennon, R. A. 2-(Alkylamino)tetralin derivatives: Interaction with 5-HT<SUB>1A</SUB> serotonin binding sites. J. Med. Chem. 1989, <U>32</U>, 253-256.</P>
<P>122.&#9;Pierson, M. E.; Lyon, R. A.; Titeler, M.; Kowalski, P.; Glennon, R. A. Design and synthesis of propranolol analogues as serotonergic agents. J. Med. Chem. 1989, <U>32</U>, 859-863.</P>
<P>123.&#9;Fitzgerald, R. L.; Blanke, R. V.; Rosecrans, J. A.; Glennon, R. A. Stereochemistry of the metabolism of MDMA to MDA. Life Sci. 1989, <U>45</U>, 295-301.</P>
<P>124.&#9;Sadzot, B.; Baraban, J. M.; Glennon, R. A.; Lyon, R. A.; Leonhardt, S.; Jan, C-R.; Titeler, M. Hallucinogenic drug interactions at human brain 5-HT<SUB>2</SUB> receptors: Implications for treating LSD induced hallucinogenesis. Psychopharmacology, 1989,<U> 98</U>, 495-499.</P>
<P>125.&#9;Glennon, R. A.; Naiman, N. A.; Pierson, M. E.; Smith, J. D.; Ismaiel, A. M.; Titeler, M.; Lyon, R. A. N-(Phthalimidoalkyl) derivatives of serotonergic agents: A common interaction at 5-HT<SUB>1A</SUB> serotonin binding sites? J. Med. Chem. <U>32</U>, 1921-1926.</P>
<P>126.&#9;Glennon, R. A.; Misenheimer, B. Stimulus effects of N-mono ethyl-(3,4-methylenedioxyphenyl)-2-aminopropane (MDE) and N-hydroxy-1-(3,4-methylenedioxyphenyl)-2-aminopropane (N-OH MDA) in rats trained to  discriminate MDMA from saline. Pharmacol. Biochem. Behav.1989, <U>33</U>, 900-912.</P>
<P>127.&#9;Glennon, R. A.; Ismaiel, A. M.; McCarthy, B. G.; Peroutka, S. J. Binding of arylpiperazines  to 5-HT3 serotonin receptors: Results of a structure-affinity study. Eur. J. Pharmacol. 1989, <U>168</U>, 387-392.</P>
<P>128.&#9;Ismaiel, A. M.; Titeler, M.; Glennon, R. A. Gamma-carboline derivatives as potential serotonergic  agents. Mansoura J. Pharm. (Egypt) 1989, <U>6</U>, 1-13.</P>
<P>129.&#9;Fitzgerald, R. L.; Blanke, R. V.; Glennon, R. A.; Yousif, M.; Rosecrans, J. A.; Poklis, A. Determination of 3,4-methylenedioxyamphetamine (MDA) and N-methyl-3,4-methylenedioxyamphetamine (MDMA) enantiomers in whole blood. J.  Chromatog. 1989,<U> 490</U>, 59-69.</P>
<P>130.&#9;Ismaiel, A. M.; Titeler, M.; Miller, K. J.; Smith, T. S.; Glennon, R. A. 5-HT<SUB>1</SUB> and 5-HT<SUB>2</SUB> binding profiles of the serotonergic agents <FONT FACE="Symbol">&#97;</FONT>-methylserotonin and 2-methylserotonin J. Med.  Chem. 1990, <U>33</U>, 755-758.</P>
<P>131.&#9;Glennon, R. A. Serotonin receptors: Clinical Implications. Neurosci. Biobehav.  Rev., 1990, <U>14</U>, 35-47.</P>
<P>132.&#9;Kerdawy, M. M.; Ismaiel, A. M.; Gineinah, M.; Glennon, R. A. A convenient synthesis of 3-aryl-1,2,4-triazolo [4,3-c]quinazolines. J. Heterocyclic Chem, 1990, <U>27</U>, 497-501.</P>
<P>133.&#9;Seggel, M. R.; Yousif, M. Y.; Lyon, R. A.; Titeler, M.; Roth, B. L.; Suba, E. A.; Glennon, R. A.  &#9;An  SAR study of the binding of 4-substituted analogues of  1-(2,5-dimethoxyphenyl)-2-aminopropane at 5-HT<SUB>2</SUB> serotonin receptors. J. Med. Chem.,  1990, <U>33</U>, 1032-1036.</P>
<P>134.&#9;Gineinah, M.; Ismaiel, A. M.; Kerdawy, M.; Glennon, R. A.  Mesoionic 1,2,4-triazolo[4,3-c]quinazolines.  J. Heterocyclic Chem., 1990, <U>27</U>, 723-726.</P>
<P>135.&#9;Glennon, R. A., Misenheimer, B. Stimulus properties of a new designer drug:  4-Methylaminorex ("U4Euh"). Pharmacol.  Biochem. Behav. 1990, <U>35</U>, 517-521.</P>
<P>136.&#9;Darmani, N., Martin, B. R., Pandey, U, Glennon, R. A. Do functional relationships exist between 5-HT<SUB>1A</SUB> and 5-HT<SUB>2</SUB> receptors?  Pharmacol. Biochem. Behav. 1990, <U>36</U>, 901-906.</P>
<P>137.&#9;Higgs, R., Glennon, R. A.  Stimulus properties of ring-methyl amphetamine analogs.  Pharmacol. Biochem. Behav. 1990, <U>37</U>, 835-837.</P>
<P>138.&#9;Glennon, R. A., Chaurasia, C., Titeler, M.  Binding of indolylalkylamines at 5-HT<SUB>2</SUB> sites: Examination of a hydrophobic binding region.  J. Med. Chem. 1990, <U>33</U>, 2777-2784.</P>
<P>139.&#9;Glennon, R. A., Raghupathi, R. K. Serotonin receptor ligands.   Current CNS Patents 1990,  <U>1</U>, 323-343.</P>
<P>140.&#9;Glennon, R. A., Battaglia, G., Smith, J. D.  (-)PPAP: A new selective ligand for sigma  binding sites.  Pharmacol.  Biochem. Behav. 1990, <U>37</U>, 557-559.</P>
<P>141&#9;Darmani, N.A., Martin, B.R., Glennon, R.A. Withdrawal from chronic treatment with (±)DOI causes both sub- and supersensitivity to 5-HT<SUB>2</SUB> receptor-induced head-twitch behaviour in mice.  Eur. J. Pharmacol. 1990, <U>186</U>, 115-118.</P>
<P>142.&#9;Darmani, N. A. , Martin, B. R., Pandey, U., Glennon, R. A.  Pharmacological classification of ear-scratch response in mice as a behavioral model for selective 5-HT<SUB>2</SUB> receptor agonists and evidence for 5-HT<SUB>1B</SUB>- and 5-HT2-receptor interactions.   Pharmacol. Biochem. Behav. 1990, <U>37</U>, 95-99.</P>
<P>143.&#9;Rydelek-Fitzgerald, L., Teitler, M., Ismaiel, A. M., Glennon, R. A. NAN-190: Agonist and antagonist interactions with brain 5-HT<SUB>1A</SUB> receptors.  Brain Res. 1990.</P>
<P>144.&#9;Yousif, M. Y., Fitzgerald, R. L., Narasimhachari, N. Rosecrans, J. A., Glennon, R.A  Identification of metabolites of 3,4-methylenedioxymethamphetamine in rats.  Drug Alcohol  Depend. 1990, <U>26</U>, 127-135.</P>
<P>145.&#9;Appel, N. M., Mitchell, W. M., Garlick, R. K., Glennon, R.  A. Teitler, M., De Souza, E. B. Autoradiographic characterization of (±)-1-(2,5,-dimethoxy-4- [<SUP>125</SUP>I]iodophenyl)-2-aminopropane ([<SUP>125</SUP>I]DOI) binding to 5-HT<SUB>2</SUB> and 5-HT<SUB>1C</SUB> receptors in rat brain.  J. Pharmacol. Exp. Ther. 1990, <U>255</U>, 843-857.</P>
<P>146.&#9;Glennon, R. A.  Do hallucinogens act as 5-HT2 agonists? Neuropsychopharmacology 1990, <U>3</U>, 509-517.</P>
<P>147.&#9;Glennon, R. A., DeVry, J., Spencer, D. G., Glaser, T. Stimulus properties of tiflucarbine: A novel antidepressant agent.  Pharmacol. Biochem. Behav. 1990.</P>
<P>148.&#9;Glennon, R. A., Smith, J. D., Ismaiel, A. M., El-Ashmawy, M., Battaglia, G., Fischer, J.B Identification and exploitation of the sigma opiate pharmacophore.  J. Med. Chem. 1991, <U>34</U>, 1094-1098.</P>
<P>149.&#9;Darmani, N., Martin, B. B., Pandey, U., Glennon, R. A. Inhibition of 5-HT<SUB>2</SUB>-mediated head-twitch response by cocaine via indirect stimulation of adrenergic alpha-<SUB>2</SUB> and serotonergic 5-HT<SUB>1A</SUB> receptors.  Pharmacol. Biochem. Behav. 1991, <U>38</U>, 353-357.</P>
<P>150.&#9;Glennon, R.A. Serotonin receptors and site-selective agents.  J. Physiol. Pharmacol. (Poland) 1991, <U>1</U>, 42-60.</P>
<P>151.&#9;Glennon, R. A., Ismaiel, A. M., Chaurasia, C., Titeler, M. 5-HT<SUB>1D</SUB> serotonin receptors:  Results of a structure-affinity investigation.  Drug Dev. Res. 1991, <U>22</U>, 25-36.</P>
<P>152.&#9;Glennon, R.A., Ismaiel, A., Smith, J.D., Yousif, M.Y., El-Ashmawy, M., Herndon, J.L., Fischer, J.B., Burke Howie, K.J., Server, A.A.  Binding of substituted and conformationally  restricted derivatives of  N-(3-phenyl-<I>n</I>-propyl)- 1-phenyl-2-aminopropane at <FONT FACE="Symbol">&#115;</FONT> receptors.  J.  Med. Chem. 1991, <U>34</U>, 1855-1859.</P>
<P>153.&#9;Glennon, R.A., El-Ashmawy, M., Ismaiel, A.M., Fischer, J.B.  Binding of N-substituted 2-phenylaminoethanes to <FONT FACE="Symbol">&#115;</FONT> and serotonin 5-HT<SUB>1A</SUB> receptors. Med. Chem. Res. 1991, <U>1</U>, 109-114.</P>
<P>154.&#9;Raghupathi, R.K., Rydelek-Fitzgerald, L., Teitler, M., Glennon, R.A.  Analogues of  the 5-HT<SUB>1A</SUB> serotonin antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimidio)-butyl]piperazine with reduced <FONT FACE="Symbol">&#97;</FONT><SUB>1</SUB>-adrenergic affinity. J. Med. Chem. 1991, <U>34</U>, 2633-2638.</P>
<P>155.&#9;Glennon, R.A., Bartyzel, P., Teitler, M. Binding of benz[e]-and benz[g]-fused tryptamine derivatives at serotonin receptors: Evidence for a region of bulk tolerance. Med. Chem. Res. 1991, <U>1</U>, 201-206.</P>
<P>156.&#9;Glennon, R.A., El-Ashmawy, M., Fischer, J.B., Burke Howie, K.J., Ismaiel, A.M. N-Substituted 5-phenyl pentylamines: A new class of <FONT FACE="Symbol">&#115;</FONT> receptor ligands. Med. Chem. Res. 1991, <U>1</U>, 207-212.</P>
<P>157.&#9;Glennon, R. A.; Darmani, N.; Martin, W. Modulation of the behavioral effects of serotonergic agents by multiple 5-HT receptors Life Sci. 1991,<U> 48</U>, 2493-2498.</P>
<P>158.&#9;Glennon, R.A.; Dukat, M. Serotonin Receptors and their Ligands: A lack of selective agents. Pharmacol. Biochem. Behav. 1991,<U> 40</U>, 1009-1017.</P>
<P>159.&#9;Glennon, R.A.; Yousif, M.Y.; Ismaiel, A.M.; El-Ashmawy, M.B.; Herndon, J.L.; Fischer,  J.B.; Server, A.C.; Burke-Howie, K.J. Novel 1-phenylpiperazines and 4-phenylpiperidines as  high-affinity sigma ligands. J. Med. Chem. 1991, <U>34</U>, 3360-3365.</P>
<P>160.&#9;Dukat, M.; Miller, K.; Teitler, M.; Glennon, R.A. Binding of amine-substituted and  quaternary amine analogs of serotonin at 5-HT<SUB>3</SUB> serotonin receptors. Med. Chem. Res.  1991, <U>1</U>, 271-276.</P>
<P>161.&#9;Bakthavachalam, V.; Fell, B.; Teitler, M.; Glennon, R.A.; Neumeyer, J.L.  Fluorescent  probes for serotonin 5-HT<SUB>1A</SUB> receptors: Synthesis, receptor affinity and selectivity. Med.  Chem. Res. 1991, <U>1</U>, 265-270.</P>
<P>162.&#9;Westkaemper, R.B.; Glennon, R.A. Approaches to molecular modeling studies and specific application to serotonin ligands and receptors.  Pharmacol. Biochem. Behav. 1991, <U>40</U>, 1019-1031.</P>
<P>163.&#9;Westkaemper, R.B.; Dukat, M.; Glennon, R.A. Molecular modeling of drug-receptor interactions using a 5-HT<SUB>2 </SUB>receptor model. Med. Chem. Res.  1991, <U>1</U>, 401-408.</P>
<P>164.&#9;Ablordeppey, S.Y.; El-Ashmawy, M.B.; Glennon, R.A. Analysis of the structure-activity relationships of sigma receptor ligands. Med. Chem.  Res. 1991,<U> 1</U>, 425-438.</P>
<P>165.&#9;Glennon, R.A. Preface for special serotonin issue of  Pharmacol. Biochem. Behav. 1991, <U>40</U>, 1007.</P>
<P>166.&#9;Glennon, R.A.; Raghupathi, R.; Bartyzel, P.; Teitler, M.; Leonhardt, S.  Binding of phenylalkylamine derivatives at 5-HT<SUB>1C</SUB> and 5-HT<SUB>2</SUB> serotonin receptors: Evidence for a Lack of  selectivity. J. Med. Chem. 1992, <U>35</U>, 734-740.</P>
<P>167.&#9;Glennon, R.A.; Young, R.; Dukat, M.  The 5-HT<SUB>3</SUB> agonist 2-methylserotonin as a training drug in drug discrimination studies.  Pharmacol. Biochem. Behav. 1992, <U>41</U>, 361-364.</P>
<P>168.&#9;El-Bermawy, M.; Raghupathi, R.; Ingher, S.P.; Teitler, M.; Maayani, S.; Glennon, R.A. 4-[4-(1-Noradamantane carboxamido)butyl]-1-(2-methoxyphenyl) piperazine: A high affinity 5-HT<SUB>1A</SUB>-selective agent. Med. Chem. Res. 1992, <U>2</U>, 88-95.</P>
<P>169.&#9;El-Ashmawy, M.; Ablordeppey, S.Y.; Issa, H.; Gad, L.; Fischer, J.B.; Burke Howie, K.J.;Glennon, R.A.  Further investigation of 5-phenylpentylamine derivatives as novel sigma receptor ligands.  Med. Chem. Res. 1992, <U>2</U>, 119-126.</P>
<P>170.&#9;El-Bermawy, M.; Lotter, H.; Glennon, R.A.  Comparative molecular field analysis of the binding of arylpiperazines at 5-HT<SUB>1A</SUB> serotonin receptors.  Med. Chem.  Res. 1992, <U>2</U>, 290-297.</P>
<P>171.&#9;Ablordeppey, S.Y.; El-Ashmawy, M.B.; Glennon, R.A.  Analysis of  the  structure-activity relationships of sigma receptor ligands.  Med. Chem. Res. 1992, <U>2</U>, 425-438.</P>
<P>172.&#9;Herndon, J.L.; Pierson, M.E.; Glennon, R.A. Mechanistic investigation of the stimulus properties of 1-(3-trifluoromethylphenyl)piperazine. Pharmacol. Biochem.  Behav. 1992, <U>43</U>, 739-748.</P>
<P>173.&#9;Glennon, R.A.; Higgs, R. Investigation of MDMA-related agents in rats trained to discriminate MDMA from saline. Pharmacol. Biochem. Behav. 1992, <U>43</U>, 759-763.</P>
<P>174.&#9;Glennon, R.A. Concepts for design of 5-HT<SUB>1A </SUB>serotonin agonists and antagonists.  Drug Dev. Res. 1992, <U>26</U>, 251-274.</P>
<P>175.&#9;Ablordeppey, S.Y.; Fischer, J.B.; Burke Howie, K.J.; Glennon, R.A.  Design, synthesis and binding of sigma receptor ligands derived from butaclamol. Med.  Chem. Res.  1992, <U>2</U>, 368-375.</P>
<P>176.&#9;Herndon, J.L.; Ismaiel, A.; Ingher, S.; Teitler, M.; Glennon, R.A. Ketanserin analogues: Structure-affinity relationships for 5-HT<SUB>2</SUB> and 5-HT<SUB>1C</SUB> serotonin receptor binding.  J. Med. Chem. 1992, <U>35</U>, 4903-4910.</P>
<P>177.&#9;Glennon, R.A.; Higgs, R.; Young, R.; Issa, H.  Further studies on N-methyl-1-(3,4-methylenedioxyphenyl)-2-aminopropane as a discriminative stimulus:  Antagonism by 5-hydroxytrptamine antagonists.  Pharmacol. Biochem. Behav. 1992, <U>43</U>, 099-1106.</P>
<P>178.&#9;Westkaemper, R.B.; Yousif, M.; Teitler, M.; Glennon, R.A.  Binding of aporphines at 5-HT<SUB>1A</SUB> serotonin receptors:  A computational investigation of potential binding modes.  Med. Chem. Res.  1992, <U>2</U>, 482-490.</P>
<P>179.&#9;Glennon, R.A.; Dukat, M.  5-HT receptor ligands:  Update 1992.  Current Drugs, 1992, <U>1</U>, 1-45.</P>
<P>180.&#9;Young, R.; Glennon, R.A. Zacopride and its optical isomers produce stereoselective antagonism of a 2-methylserotonin discriminative stimulus.  Eur. J. Pharmacol. 1992,  <U>212</U>,  117-119.</P>
<P>181.&#9;Glennon, R.A.; Maarouf, R.; Fahmy, S.; Martin, B.; Fan, F.; Yousif, M.; Shafik, R.; Dukat, M. Structure-affinity relationships of simple nicotine analogs.  Med. Chem.  es. 1993, <U>2</U>, 546-551.</P>
<P>182.&#9;Young, R.; Glennon, R.A. Cocaine-stimulus generalization to two new designer drugs:  Methcathinone and 4-methylaminorex. Pharmacol. Biochem. Behav. 1993, <U>45</U>, 229-231.</P>
<P>183.&#9;Young, R.; Herndon, J.L.  Antagonism of a (+)N-allylnormetazocine  stimulus by (-)PPAP and several structurally related analogs.  Pharmacol. Biochem. Behav.  1993, <U>45</U>, 865-869.</P>
<P>184.&#9;Ablordeppey, S.Y.; Issa, H.; Fischer, J.B.; Burke Howie, K.J.; Glennon, R.A.  Synthesis and structure-affinity relationship studies of sigma ligands related to haloperidol.  Med. Chem. Res. 1993, <U>3</U>, 131-138.</P>
<P>185.&#9;Ismaiel, A.M.; De Los Angeles, J.; Teitler, M.; Ingher, S.; Glennon, R.A.  Antagonism of 1-(2,5-dimethoxy-4-methylphenyl)-2 aminopropane stimulus with a newly identified 5-HT2- versus 5-HT1C-selective antagonist.  J. Med. Chem. 1993, <U>36</U>, 2519-2525.</P>
<P>186.&#9;Glennon, R.A.  MDMA-like stimulus effects of  <FONT FACE="Symbol">&#97;</FONT>-ethyltryptamine and the <FONT FACE="Symbol">&#97;</FONT>-ethyl homolog of DOM. Pharmacol. Biochem. Behav. 1993, <U>46</U>, 459-462.</P>
<P>187.&#9;Westkaemper, R.B. and Glennon, R.A.  Molecular graphics models of members of the 5-HT<SUB>2</SUB> subfamily: 5-HT<SUB>2A</SUB>, 5-HT<SUB>2B</SUB>, and 5-HT<SUB>2C </SUB>receptors.  Med. Chem. Res.  1993, <U>3</U>, 317-334.</P>
<P>188.&#9;Abou-Gharbia, M.; Ablordeppey, S.Y.; Glennon, R.A.  Sigma receptors and their ligands: The Sigma Enigma.  Annual Reports in Medicinal Chemistry.  1993, <U>28</U>, 1-10.</P>
<P>189.&#9;Glennon, R.A., Westkaemper, R.B.  5-HT<SUB>1D</SUB> Receptors:  A serotonin receptor population for the 1990s.  Drug News Perspect. 1993,<U> 6</U>, 390-405.</P>
<P>190.&#9;Dukat, M.; Damaj, M.I.; Glassco, W.; Dumas, D.; May, E.L.; Martin, B.R.; Glennon, R.A. Epibatidine:  A very high affinity nicotine-receptor ligand.  Med. Chem. Res.  1994, <U>4</U>, 131-139.</P>
<P>191.&#9;Damaj, M.I.; Glennon, R.A.; Martin, B.R.  Involvement of the serotonergic system in the hypoactive and antinociceptive effects of nicotine in mice. Brain Res. 1994, <U>33</U>, 199-203.</P>
<P>192.&#9;Glennon, R. A.; Ablordeppey, S. Y.; Ismaiel, A. M.; El-Ashmawy, M. B.; Fischer, J. B.; and Burke-Howie, K.  Structural features important sigma-1 (<FONT FACE="Symbol">&#115;</FONT>-<SUB>1</SUB>) receptor binding.  J. Med. Chem. 1994, <U>37</U>, 1214-1219.</P>
<P>193.&#9;Carroll, F.I.; Glennon, R.A.; Johnson, M.R.; Teitler, M.; Zimmerman, D.M.  Hallucinogenic Agents: Drugs of abuse as neurochemical tools. NIDA Res. Mono.  1994, <U>140</U>, 94-98.</P>
<P>194.&#9;Glennon, R.A.; Dukat, M.; El-Bermawy, M.; Law, H.; De Los Angeles, J.; Teitler, M.; King, A.; &#9;Herrick-Davis, K.  Influence of amine substituents on 5-HT<SUB>2A</SUB> versus 5-HT<SUB>2C</SUB> binding of phenylalkyl- and indolylalkylamines.  J. Med. Chem. 1994, <U>37</U>, 1929-1935</P>
<P>195.&#9;Dukat, M.; Herrick-Davis, K.; Teitler, M.; Glennon, R.A.  Piperidine derivatives of serotonin as selective 5-HT<SUB>1A</SUB> serotonin receptor agonists.  Med.Chem.Res. 1994, 4, 254-258.</P>
<P>196.&#9;Glennon, R.A.; Hong, S-S.; Dukat, M.; Teitler, M. and Davis, K.  5-(Nonyloxy)tryptamine: A novel high-affinity 5-HT<SUB>1D&szlig;</SUB> serotonin receptor agonist.  J. Med. Chem. 1994, <U>37</U>, 2828-2830.</P>
<P>197.&#9;Glennon, R.A.; Herndon, J.L.; Dukat, M.  Epibatidine-aided studies toward definition of a nicotine receptor pharmacophore.  Med. Chem. Res.  1994, 4:461-473.</P>
<P>198.&#9;Choudhary, M.S.; Sachs, N.; Ulver, A.; Glennon, R.A.; Westkaemper, R.B.; Roth, B.L. Differential ergoline and ergopeptine binding to 5-HT<SUB>2A</SUB> receptors:  Ergolines require an aromatic residue at position 340 for high affinity.  Mol. Pharmacol. 1995, 47: 450-457.</P>
<P>199.&#9;Ismaiel, A.M.; Aruda, K.; Teitler, M.; Glennon, R.A.  Ketanserin analogues: the effect of structural modification on 5-HT<SUB>2</SUB> serotonin receptor binding.  J. Med. Chem. 1995, 38, 1196-1202.</P>
<P>200.&#9;Glennon, R.A.; Young, R.; Martin, B.; Dal Cason, T.  Methcathinone ("CAT"):  An enantiomeric potency comparison.  Pharmacol. Biochem. Behav. 1995, <U>50</U>, 601-601.</P>
<P>201.&#9;Hong, S.-S.; Dukat, M.; Teitler, M.; Herick-Davis, K.; McCallum, K.; Kamboj, R.; Glennon, R.A.  Binding of 5-arylalkyloxytryptamines at human 5-HT<SUB>1D&szlig;</SUB> serotonin  receptors. Med. Chem. Res.  1995, 5:690-699.</P>
<P>202.&#9;Glennon, R.A.; Hong, S.-S.; Bondarev, M.; Law, H.; Dukat, M.; Rakhit, S.; Power, P.; Fan, E.; Kinneau, D.; Kamboj, R.; Teitler, M.; Herrick-Davis, K.; Smith. C.  Binding of O-alkyl derivatives of serotonin at human 5-HT<SUB>1D&szlig;</SUB> receptors.  J. Med. Chem. 1996, <U>39</U>, 314-322.</P>
<P>203.&#9;Glennon, R.A.; Dukat, M.; Westkaemper, R.B.; Ismaiel, A.M.; Izzarelli, D.G.; Parker, E.M. The binding of propranolol at 5-hydroxytryptamine<SUB>1D&szlig; </SUB>T355N mutant receptors may  involve formation of two hydrogen bonds to asparagine.  Mol. Pharm. 1996, 49, 198-206.</P>
<P>204.&#9;Young, R.; Glennon, R.A.  A three-lever operant procedure differentiates the stimulus effects of R(-)-MDA from S(+)-MDA.  J. Pharmacol. Exp. Ther. 1996, 276, 594-601.</P>
<P>205.&#9;Ismaiel, A.M. Dukat, M., Nelson, D.L. Lucaites, V.L.; Glennon, R.A.  Binding of N<SUB>2</SUB>-substituted pyrido[4,3-b]indole analogs of spiperone at human 5-HT<SUB>2A</SUB>, 5-HT<SUB>2B</SUB>, and 5-HT<SUB>2C</SUB> serotonin receptors. Med. Chem. Res. 1996, 6, 197-211.</P>
<P>206.&#9;Glennon, R.A.; Fiedler, W.; Dukat, M.; Damaj, I.; Martin, B. Pyrrolidine-modified analogues of nicotine: a structure-affinity investigation.  Eur. J. Med. Chem.1996, in press.</P>
<P>207.&#9;Glennon, R. A.; Young, R.; Dukat, M.; Cheng, Y. Initial characterization of PMMA as a discriminative stimulus. Pharmacol. Biochem. Behav. 1996, in press.</P>
<P>208.&#9;Young, R. A.; Glennon, R. A. Cocaine-stimulus generalization to MDA optical isomers: A re-evaluation. Pharmacol. Biochem. Behav. 1996, in press.</P>
<P>209.&#9;Iwamura, T.; Casey, C. T.; Young, R.; Dukat, M.; Teitler, M.; Fadden, J. S. P.; Glennon, R. A. 4-(6-Fluorobenzisoxazol-3-yl)piperidine, a risperidone metabolite with serotonergic activity of potential clinical significance. Med. Chem. Res. 1996, in press.</P>
<P>210.&#9;Young, R.; Darmani, N. A.; Elder, E. L.; Dumas, D.; Glennon, R. A. Clobenzorex: Evidence for amphetamine-like behavioral actions. Pharmacol. Biochem. Behav. 1996, in press.</P>
<P>211.&#9;Glennon, R. A.; Dukat, M. Nicotine receptor ligands. Med. Chem. Res. 1996, in press.</P>
<P>212.&#9;Dukat, M.; Abdel-Rahman, A. A.; Ismaiel, A. M.; Ingher, S.; Teitler, M.; Gyermek, L.; Glennon, R. A. Structure-activity relationships for the binding of arylpiperazines and arylbiguanides at 5-HT<SUB>3</SUB> serotonin receptors. J. Med. Chem. 1996, 39, 20, 4017-4026.</P>
<P>213.&#9;Malmusi, L.; Dukat, M.; Young, R.; Teitler, M.; Darmani, N.A.; Ahmad, B.; Smith, C.; and Glennon, R.A.  1,2,3,4-Tetrahydroisoquinoline and related analogs of the phenylalkylamine designer drug MDMA.  Med. Chem. Res., 1996, 412-426.</P>
<P>214.&#9;Malmusi, L.; Dukat, M.; Young, R.; Teitler, M.; Darmani, N.A.; Ahmad, B.; Smith C.; and Glennon, R.A..  1,2,3,4-Tetrahydroisoquinoline analogs of phenylalkylamine stimulants and hallucinogens.  Med. Chem. Res., 1996, 400-411.</P>

<hr>

<h3>Book Chapters</h3>

<P> 1.&#9;Glennon, R. A.; Rosecrans, J. A.; Young, R. The use of the drug discrimination paradigm for studying hallucinogenic agents. In: <U>Drug Discrimination: Applications in CNS Pharmacology</U>, F. C. Colpaert and J. L. Slangen eds., Elsevier Biomedical Press, Amsterdam, 1982. pp 69-96.</P>
<P> 2.&#9;Glennon, R. A. Hallucinogenic Phenylisopropylamines: Stereochemical Aspects. In: <U>Stereoisomers: Drugs in Psychopharmacology</U>, D. Smith ed., CRC Press, Boca Raton, 1983. pp 327-370.</P>
<P> 3.&#9;Nichols, D. E.; Glennon, R. A. Medicinal Chemistry and Structure-Activity Relationships of Hallucinogenic Agents. In: <U>Hallucinogens: Neurochemical, Behavioral, and Clinical Perspectives</U>,  B. Jacobs ed., Raven Press, NY 1984. pp 95-142.</P>
<P> 4.&#9;Glennon, R. A. Interaction of hallucinogenic agents with serotonin receptors. In: <U>Medicinal Chemistry</U>, R. Dahldom and J. L. G. Nilsson, eds., Swedish Pharmaceutical Press, Stockholm 1985. pp 116-129.</P>
<P> 5.&#9;Glennon, R. A. The role of serotonin in the mechanism of action of hallucinogenic agents. In: <U>Neuropharmacology of Serotonin</U>, A. R. Green, ed., Oxford University Press, 1985.</P>
<P> 6.&#9;Arvidsson, L. E.; Hacksell, U.; Glennon, R. A. Recent advanc-es in central  5-hydroxytryptamine receptor agonists and an-tagonists. In: <U>Progress in Drug Research</U>, E.  Jucker, ed., Birkhauser Verlag, Basel, 1986. pp 365-471.</P>
<P> 7.&#9;Glennon, R. A. Discriminative stimulus properties of site-selective serotonin agonists. In: <U>Transduction Mechanisms of Drug Stimuli</U>, F. C. Colpaert and R. L. Balster eds., Springer  &#9;Verlag, Berlin, 1988. pp 15-32.</P>
<P> 8.&#9;Glennon, R. A.; Young, R. Use of the drug discrimination paradigm for investigating  structure-activity relationships, in <U>Drug Dependence</U>, M. Bozarth ed., Springer-Verlag, NY, 1987. pp 373-390.</P>
<P> 9.&#9;Glennon, R. A. Psychoactive Phenylisopropylamines. In: <U>Psychopharmacology, Third Generation of  Progress</U>, H. Meltzer ed., Raven Press, 1987. pp 1627-1634.</P>
<P>10.&#9;Young, R.; Glennon, R. A. Second generation anxiolytics and serotonin, In: <U>Serotonin:Behavioral Pharmacology</U>, R. H.  Rech and G. A.  Gudelsky eds. NPP Press, Ann Arbor MI, 1988. pp 239-258.</P>
<P>11.&#9;Glennon, R. A.; Lucki, I. Behavioral aspects of serotonin agonists", In:<U> Serotonin Receptors</U>, E. Sanders-Bush ed., Humana Press, NJ, 1988. pp 253-294.</P>
<P>12.&#9;Glennon, R. A. Central serotonin receptors, In: <U>Receptor Pharmacology and Function</U>, M. Williams, R. A. Glennon and P. Timmermans eds., M. Dekker, 1989. pp 257-292.</P>
<P>13.&#9;Glennon, R. A.; Young, R.; Pierson, M. E. Stimulus properties of arylpiperazine second &#9;generation anxiolytics. In: <U>The Behavioral Pharmacology of 5-HT</U>, P. Bevan, A. R. Cools, and T. Archer, eds. Lawrence Earlbaum Associates, NY, 1989. pp 445-449.</P>
<P>14.&#9;Glennon, R. A.; Seggel, M. R. Interaction of phenylisopropylamines with 5-HT2 receptors: A QSAR analysis. in <U>Bioactive Mechanisms</U>, Magee, P. S. ed. ACS Press, Washinton DC, 1989.</P>
<P>15.&#9;Glennon, R. A. Synthesis and evaluation of amphetamine analogs: A review. In: <U>Clandestinely Produced Drugs, Analogues, and Precursors</U>, M. Klein, F. Sapienza, H. McClain and I. Khan, eds. US Government Printing Office, Washington DC, 1989. pp 39-65.</P>
<P>16.&#9;Glennon, R. A. "Stimulus Properties of Hallucinogenic Phenalkylamines and Related Designer Drugs: Formulation of Structure-Activity Relationships" In: <U>Pharmacology and Toxicology of Amphetamine and Related Designer Drugs</U>, Ashgar, R.  DeSouza, E. eds., U.S. &#9;Government Printing Office, Washington, DC., 1989 pp 43-67.</P>
<P>17.&#9;Teitler, M.; Leonhardt, S.; Appel, N. M.; DeSouza, E. B.; Glennon, R. A. "Receptor pharmacology of MDMA and related hallucinogens" In: <U>The Neuropharmacology of Serotonin</U>, Peroutka, S., ed., New York Academy of Science, New York, 1990. pp. 626-638.</P>
<P>18.&#9;Glennon, R. A., Westkaemper, R., Bartyzel, P. "Medicinal Chemistry of Serotonergic Agents" In: <U>Serotonin Receptor Subtypes</U>  Peroutka, S. ed., Wiley-Liss, NY, 1991. pp. 19-64.</P>
<P>19.&#9;Glennon, R. A. Serotonergic agents and CNS receptors, in <U>Advances in CNS Drug-Receptor Interactions</U>, J. Cannon, ed.  JAI Press, Greenwich. 1991.</P>
<P>20.&#9;Glennon, R. A., Tejani, S.  "Mesoionic Nucleosides and Heterobases" In: <U>Chemistry of Nucleosides and Nucleotides</U>, L.  Townsend, ed., Plenum Press, 1991. pp. 1-21.</P>
<P>21.&#9;Glennon, R.A., Peroutka, S.J., Dukat, M.  "Binding characteristics of a quaternary amine analog of serotonin: 5-HTQ", In:<U> Serotonin: Molecular Biology, Receptors and Functional Effects</U>, J. R. Fozard and P. R. Saxena, eds., Birkhauser-Verlag, Basel, 1991. pp. 186-191.</P>
<P>22.&#9;Glennon, R. A. "Animal Models for Assessing Hallucinogenic Agents" In: <U>Animal Models for Assessing Hallucinogenic Agents</U>, Boulton, A.; Baker, G.; Wu, P.; ed., Humana Press, Clifton, New Jersey, 1992. pp. 345-381.</P>
<P>23.&#9;Glennon, R.A. &quot;Discriminative Stimulus Properties of Hallucinogens and Related Designer Drugs&quot; In: <U>Drug Discrimination: Application in Drug Abuse Research</U>, NIDA Research Monograph, R.A. Glennon, T. Jarbe and J. Frankenhein, eds., Washington DC, 1991. pp. 25-44.</P>
<P>24.&#9;Glennon, R.A. &quot;Phenalkylamine Stimulants, Hallucinogens and Designer Drugs&quot; In: <U>Proceedings of the 1990 CPDD Meeting</U>, L.S. Harris, ed., Washington DC, 1990.  pp. 154-160.</P>
<P>25.&#9;Glennon, R.A.; Westkaemper, R.B. &quot;Serotonin Receptors, 5-HT Ligands and Receptor Modeling&quot; In: <U>Trends in Receptor Research</U>, P. Angeli, U. Gulini and W. Quaglia, eds, Elsevier, Amsterdam, 1992.  pp. 185-207.</P>
<P>26.&#9;Glennon, R.A. Classification of agents used in serotonin research. In: <U>Serotonin</U>, P. M. Vanhoutte, P. R. Saxena, R. Paoletti, N. Brunello, A. S. Jackson, eds., Kluwer Academic Publishers, Dordrecht, 1993. pp 49-54.</P>
<P>27.&#9;Glennon, R.A.  "Classical hallucinogens, an introductory overview".  In:<U> Hallucinogens: An Update</U>.  G.C. Lin and R.A. Glennon, eds., U.S. Government Printing Office, Washington, D.C. 1994. pp. 4-32.</P>
<P>28.&#9;Westkaemper, R.B.; Glennon, R.A.  "Molecular modeling of the interaction of LSD and other hallucinogens with 5-HT2 receptors".  In: <U>Hallucinogens: An Update.</U>  G.  C. Lin and R.A. Glennon, eds., U. S. Government Printing Office, Washington, D.C.  1994. pp. 263-283.</P>
<P>29.&#9;Herndon, J.L.; Glennon, R.A.<U> Serotonin receptors, agents, and actions. In: Drug Design for Neuroscience</U>, A.P. Kozikowski, ed. Raven Press, NY, 1993. pp 167-212.</P>
<P>30.&#9;Glennon, R.A.; Dukat, M.  "Serotonin Receptor Subtypes".  In: <U>Psychopharmacology: The fourth generation of progress</U>.  Bloom, R.E.; Kupfer, D.J.; Raven Press 1994, 415-429.</P>
<P>31.&#9;Glennon, R.A. How do LSD and LSD-related hallucinogens work? In: <U>Hallucinogens, LSD</U>, <U>and Raves</U>.  Proceedings of the Scientific Advisory Board of the American Council for Drug Education, American Council for Drug Education, Washington, D. C. 1994.  pp 14-20.</P>
<P>32.&#9;Glennon, R.A.; Dukat, M. Serotonin Subfamily of receptors. In: <U>The RBI Handbook of Receptor Classification</U>.  J.W. Kebabian and J.L. Neumeyer, eds., Research Biochemicals International, Natick, 1994.  pp. 58-61..</P>
<P>33.&#9;Glennon, R.A. Sigma receptors. In: <U>The RBI Handbook of Receptor Classification</U>. J. W. Kebabian and J. L.  Neumeyer, eds.,  Research Biochemicals International, Natick, 1994. pp  62-63.</P>
<P>34.&#9;Dukat, M.; Damaj, M.I.; Dumas, D.; Glassco, W.; May, E.L.; Martin, B.R.; Glennon, R.A.  "Epibatidine". In: <U>Effects of Nicotine on biological systems II (APS)</U>. P.B.S. Clarke, M. Quik, K. Thurau, F. Adlkofer, eds., Birkhauser, Basel, Switzerland, 1995.</P>
<P>35.&#9;Glennon, R.A.  "Classical Hallucinogens".  In: <U> Handbook of Experimental Pharmacology:</U> <U> Pharmacological Aspects of Drug Dependence</U>. C. R. Schuster and M. J. Kuhar, eds., Springer Verlag, Basel, 1996. pp 343-371.</P>
<P>36.&#9;Glennon, R.A.; Dukat, M.  Serotonin receptors and ligands. In: <U>Introduction to the Principles of Drug Design and Action</U>  H. J. Smith, ed. in press.</P>

<hr>

<h3>Books Edited</h3>

<P> 1.&#9;<U>Receptor Pharmacology and Function</U>,  M. Williams, R. A. Glennon and P. Timmermans eds., M. Dekker, New York, 1989.</P>
<P> 2.&#9;<U>Drug Discrimination: Applications in Drug Abuse Research</U>, R. A. Glennon, T. Jarbe and J Frankenheim, U.S. Government Printing Office, Washington DC, 1991.</P>
<P> 3.&#9;<U>Hallucinogens:  An Update</U>, G.C. Lin and R.A. Glennon, eds, U.S.  Government Printing Office, Washington, D.C. 1994.</P>

<hr>

<h3>PATENTS</h3>

<P>1.&#9;Glennon, R. A. Tryptamine analogs with 5-HT<SUB>1D</SUB> selectivity. US Patent 5,496,957 (March 5, 1996).</P>
<P>2.&#9;Glennon, R. A. 5-HT1D receptor ligands. US Patent 5,504,101 (April 2, 1996).</P>

<hr>
</td></tr>
</table>
</center>
</body>
</html>
